taVNS in Mild to Moderate Parkinson's Disease
taVNS in Mild to Moderate Parkinson's Disease
The purpose of this study is to find out whether a non-invasive form of nerve stimulation
 called transcutaneous vagus nerve stimulation (taVNS) is safe and effective in people with
 Parkinson's Disease.
Inclusion Criteria:

 -  Age: 40-79 y

 -  Idiopathic Parkinson's Disease Diagnosis

 -  Disease Stage: Hoehn and Yahr stage 2-3

 -  Patient requires a minimum of 3 doses of levodopa daily

 -  Willingness to be videotaped

 Exclusion criteria:

 -  Dementia or Montreal Cognitive Assessment score <24

 -  Parkinson's Disease psychosis

 -  Ear trauma

 -  Facial pain

 -  Traumatic Brain Injury or clinical history of stroke

 -  Metal implants above the shoulders

 -  History of myocardial infarction or arrhythmia, bradycardia

 -  Active respiratory disorder

 -  Alcohol or substance use disorders

 -  History of Deep Brain Stimulation (DBS) or other brain surgery

 -  Epilepsy

 -  Pregnancy

 -  B-Blockers, dopamine blocking agent, antiarrhythmic medication, acetylcholine esterase
 inhibitor, midodrine, florinef, droxidopa, or anticholinergic drugs